Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as it continues to avoid a $54bn hostile takeover bid from Valeant Pharmaceuticals.
Rhodia has revealed the extent of job cuts that will take place in
the wake of its restructuring exercise, initiated in response to
the financial pressures facing the chemicals group.